Home World News Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer World News Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 227 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Withdrawal of the Application to Change the EMA Marketing Authorisation for... December 2, 2022 Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Singer Rebecca Crews, Wife Of Terry Crews, Diagnosed With Breast Cancer... April 13, 2020 Stem cell research: meet the scientist growing ‘mini guts’ in her... April 8, 2022 Load more HOT NEWS What Are Drug Shortages and How Can They Impact Care for... 10-Year Data Underscore How ICI Therapy Has Helped to Change the... News digest – cancer blood test, gum disease and junk food... FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer
